Teladoc Health (NYSE:TDOC) Price Target Cut to $25.00

Teladoc Health (NYSE:TDOC) had its price objective cut by equities researchers at Canaccord Genuity Group from $28.00 to $25.00 in a research report issued on Friday, Benzinga reports. The brokerage presently has a “buy” rating on the health services provider’s stock. Canaccord Genuity Group’s price objective would suggest a potential upside of 87.55% from the stock’s previous close.

A number of other brokerages have also recently commented on TDOC. Citigroup lowered their target price on Teladoc Health from $21.00 to $19.00 and set a “neutral” rating on the stock in a report on Wednesday, February 21st. Needham & Company LLC restated a “hold” rating on shares of Teladoc Health in a report on Friday. Leerink Partnrs restated a “market perform” rating on shares of Teladoc Health in a report on Monday, February 26th. Piper Sandler decreased their price objective on Teladoc Health from $30.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, February 21st. Finally, Barclays decreased their price objective on Teladoc Health from $26.00 to $25.00 and set an “overweight” rating on the stock in a report on Wednesday, February 21st. Eight analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $22.00.

Teladoc Health Stock Performance

Shares of TDOC stock opened at $13.33 on Friday. The company has a market cap of $2.26 billion, a price-to-earnings ratio of -9.95 and a beta of 0.94. The stock has a 50 day simple moving average of $15.17 and a 200-day simple moving average of $17.80. Teladoc Health has a 12-month low of $12.85 and a 12-month high of $30.41. The company has a current ratio of 3.54, a quick ratio of 3.47 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last released its quarterly earnings data on Thursday, April 25th. The health services provider reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.47) by ($0.02). Teladoc Health had a negative net margin of 8.47% and a negative return on equity of 9.22%. The firm had revenue of $646.13 million during the quarter, compared to analysts’ expectations of $637.31 million. During the same period in the previous year, the business earned ($0.37) earnings per share. The business’s revenue for the quarter was up 2.7% on a year-over-year basis. On average, equities analysts forecast that Teladoc Health will post -1.07 EPS for the current year.

Insider Buying and Selling at Teladoc Health

In other Teladoc Health news, insider Laizer Kornwasser sold 7,882 shares of the firm’s stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $19.18, for a total value of $151,176.76. Following the transaction, the insider now directly owns 57,223 shares of the company’s stock, valued at $1,097,537.14. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other Teladoc Health news, EVP Andrew Turitz sold 6,190 shares of the firm’s stock in a transaction dated Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $89,878.80. Following the transaction, the executive vice president now directly owns 39,429 shares of the company’s stock, valued at $572,509.08. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Laizer Kornwasser sold 7,882 shares of Teladoc Health stock in a transaction dated Friday, February 2nd. The stock was sold at an average price of $19.18, for a total value of $151,176.76. Following the sale, the insider now directly owns 57,223 shares in the company, valued at $1,097,537.14. The disclosure for this sale can be found here. Insiders have sold 135,441 shares of company stock valued at $2,038,251 over the last three months. 1.63% of the stock is owned by company insiders.

Institutional Trading of Teladoc Health

Hedge funds and other institutional investors have recently modified their holdings of the business. Commonwealth Equity Services LLC increased its holdings in Teladoc Health by 5.7% in the third quarter. Commonwealth Equity Services LLC now owns 80,934 shares of the health services provider’s stock valued at $1,505,000 after buying an additional 4,344 shares during the last quarter. Robeco Institutional Asset Management B.V. boosted its stake in Teladoc Health by 49.4% in the third quarter. Robeco Institutional Asset Management B.V. now owns 453,861 shares of the health services provider’s stock valued at $8,437,000 after acquiring an additional 149,976 shares during the period. Raymond James & Associates boosted its stake in Teladoc Health by 0.9% in the third quarter. Raymond James & Associates now owns 228,238 shares of the health services provider’s stock valued at $4,243,000 after acquiring an additional 2,029 shares during the period. Mackenzie Financial Corp boosted its stake in Teladoc Health by 83.7% in the third quarter. Mackenzie Financial Corp now owns 30,843 shares of the health services provider’s stock valued at $570,000 after acquiring an additional 14,050 shares during the period. Finally, Allspring Global Investments Holdings LLC boosted its stake in Teladoc Health by 8.8% in the third quarter. Allspring Global Investments Holdings LLC now owns 50,903 shares of the health services provider’s stock valued at $946,000 after acquiring an additional 4,129 shares during the period. 76.82% of the stock is owned by hedge funds and other institutional investors.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.